PF-04620110

Confirm delete?

PF-04620110

Zoom

Cat No: 16425

Biochemicals - Small Molecule Inhibitors

Acyl-CoA:diacylglycerol acyltransferase-1 (DGAT-1) catalyzes the final committed step in the biosynthesis of triglycerides and has potential roles in obesity, diabetes, and atherosclerosis.{12021,15816,10960} PF-04620110 is a potent inhibitor of DGAT-1...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

trans-4-[4-(4-amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]-cyclohexaneacetic acid

Correlated keywords:

obesity inhibitors atherosclerosis diabetes biochemicals no effects DGAT-2 DGAT2 DGAT1 DGATs 2s 1s twos ones oral orally bioavailability bioavailabilities bios availability availabilities rats moderate half-life half life blocks increases increasing plasmas triglycerides levels corns oils boluses oil-boluses corn-oils 1109277-11-3 PF04620110 PFs 04620110

Product Overview:
Acyl-CoA:diacylglycerol acyltransferase-1 (DGAT-1) catalyzes the final committed step in the biosynthesis of triglycerides and has potential roles in obesity, diabetes, and atherosclerosis.{12021,15816,10960} PF-04620110 is a potent inhibitor of DGAT-1 (IC50 = 19 nM) that is without effect on DGAT-2.{26854} It has high oral bioavailability (100%) in rats, with a moderate half-life of 6.8 hours.{26854} PF-04620110 significantly blocks an increase in plasma triglyceride levels following a corn oil bolus in rats.{26854}

Size	5 mg
Shipping	dry ice
CAS Number	1109276-89-2
Molecular Formula	C₂₁H₂₄N₄O₄
SMILES	OC(C[C@@H]1CC[C@@H](C2=CC=C(N3CCOC(N=CN=C4N)=C4C3=O)C=C2)CC1)=O
Molecular Weight	396,4
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2921.59
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.